Skip to content

Physiological Reconditioning Program Administered Remotely in Patients Undergoing Transcatheter Aortic Valve Replacement: A Pilot Study

Physiological Reconditioning Program Administered Remotely in Patients Undergoing Transcatheter Aortic Valve Replacement Pilot Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03801460
Acronym
PREPARE-TAVR
Enrollment
160
Registered
2019-01-11
Start date
2020-07-01
Completion date
2022-03-31
Last updated
2021-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frailty, Rehabilitation, Transcatheter Aortic Valve Replacement

Brief summary

The PREPARE TAVR pilot study will examine the effects of remotely administered physiological reconditioning program (RAPR) on quality of life (QOL) and clinical outcomes at one year post TAVR in frail older adults.

Detailed description

The main objective of this study is to evaluate the effects of a home based exercise and dietary intervention program on the quality of life (QOL) and clinical outcomes in frail adults undergoing Transcatheter aortic valve replacement (TAVR) procedures. Patients will be randomly (1:1) assigned to the standard of care (SOC group) where patients will receive all medical care as decided by their treating physicians or assigned to a home based program known as remotely administered physiological reconditioning (RPR) program which will include receiving personalized instructions for a progressive exercise program and dietary changes. Patients will be contacted for regular phone and in-person follow up for monitoring their progress. The primary endpoint will be quality of life as assessed by KCCQE questionnaires at one-year post TAVR. The secondary endpoints include length of stay post TAVR, all-cause mortality, repeat hospitalization and a composite of all-cause mortality and repeat hospitalization at one year.

Interventions

OTHERRemotely administered physiological reconditioning program

Patients assigned to intervention arm will be provided a personalized, tailored and graduated exercise program to improve physical strength and conditioning.

Sponsors

Unity Health Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

The outcomes assessed in a blinded manner

Intervention model description

Prospective, multicenter, randomized trial with objective end points assessment

Eligibility

Sex/Gender
ALL
Age
60 Years to 95 Years
Healthy volunteers
No

Inclusion criteria

\- Short Physical Performance Battery Protocol (SPPB) score \< 9

Exclusion criteria

* Severe liver disease defined by Childs Pugh class \>B or MELD score \>15. * Severe kidney disease defined by eGFR \<30 mL/min. * Hospital admission during the 4 weeks prior to randomization. * Montreal objective cognitive assessment (MOCA) score \<18. * Mechanical fall in the past month. * Unstable angina during the previous month. * Myocardial infarction during the previous month. * Unsuccessful completion of the one-week run-in phase. * Syncopal episode during exercise during run-in phase

Design outcomes

Primary

MeasureTime frameDescription
Quality of Life (QOL)One yearQuality of life as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ). KCCQE is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life (QOL) within a 2-week recall period. KCCQ responses are provided along a rating scale continuum with equal spacing from worst to best.

Secondary

MeasureTime frameDescription
LOSIndex hospitalizationLength of stay post TAVR
MACEone yearComposite of mortality and repeat hospitalization

Countries

Canada

Contacts

Primary ContactSyed Ishba
ishba.syed@unityhealth.to416-620-9600

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026